User Fee Revision Reduces Expected CDER Staffing Increases By 60%
This article was originally published in The Tan Sheet
Executive Summary
A revision of FDA's estimated revenues from user fees will reduce the expected additions in staff to the Center for Drug Evaluation & Research to 40% of previous estimates.
You may also be interested in...
FDA Wants More "Predictable" Revenue Stream Under PDUFA III
FDA would like to ensure a more "predictable" revenue stream under the third Prescription Drug User Fee Act.
User Fee Workload Decline Leads To Staff Decreases In Regulatory Affairs
FDA's Office of Regulatory Affairs will reduce its Prescription Drug User Fee Act II-funded staff by 40 full-time equivalents for each of the remaining two years of the act's authorization period. The plan calls for 10 fewer FTEs in fiscal 1999, and for 40 fewer FTEs in each subsequent year through 2002.
FDA Employees Not Required To Agree On Approvals - Union Contract
FDA employees in a "concurrence chain" are no longer required to concur with a product approval document with which he or she professionally disagrees, according to the ratified contract of the FDA chapters of the National Treasury Employees Union.